Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MedImmune and NGM Biopharmaceuticals Announce Agreement

Published: Wednesday, June 19, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Agreement to discover and develop therapies for diabetes and obesity.

AstraZeneca has announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM’s enteroendocrine cell (EEC) programme for the treatment of type 2 diabetes and obesity.

EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the known GI hormones, including GLP-1.

EECs are an underexplored source of novel hormones that could play a major role in the positive and negative regulation of metabolism and glucose homeostasis.

NGM has established a proprietary platform capable of isolating and analyzing EECs in order to identify novel secreted peptide hormones that are potentially linked to the profound metabolic effects of bariatric surgery and serve as potential targets for the treatment of metabolic diseases.

MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones.

MedImmune will have the option to license in these EEC targets, and will be responsible for the global development, manufacture and commercialization of compounds resulting from the collaboration.

“We believe that hormones found in the gastrointestinal tract can play an important role in resolving diabetes after bariatric surgery. Through NGM’s innovative research in metabolic disease, we believe our collaboration could lead to potential innovative medicines for diabetes and obesity that will make a difference in patients’ lives,” said Cristina Rondinone, Ph.D., Head of Cardiovascular and Metabolic Disease Innovative Medicines Unit, MedImmune.

Rondinone continued, “Our partnership with NGM complements AstraZeneca’s existing small molecule and biologics portfolio in cardiovascular and metabolic disease, one of our core therapy areas.”

Under the terms of the agreement, MedImmune will make an upfront payment and provide NGM research funding over the course of the collaboration.

If certain development, regulatory and commercial milestones are achieved, NGM will be entitled to receive various payments, as well as royalties on worldwide product sales.

“We are excited to enter into this strategic partnership with MedImmune as it represents a unique opportunity to maximize the full complement of novel hormones secreted by these EECs for drug discovery purposes,” said Jin-Long Chen, Ph.D., founder, president and chief scientific officer of NGM.

Chen continued, “Together, NGM and MedImmune will build upon the culture of scientific excellence at both organizations. With MedImmune’s deep biologics and development expertise, we are confident that we will further enrich the pipeline of therapies for the treatment of diabetes and obesity.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Adipose Tissue Secretes Factors That Activate Metabolism
Study finds brown adipose tissue secretes signalling factors that activates metabolism of fat and carbohydrates.
Gene Deletion Reveals Cell Secrets
Researchers have deleted 174 genes in yeast to analyse the effect of individual gene deletion.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
NIH Study Finds Link Between Depression, Gestational Diabetes
Researchers at NIH have discovered that the depression in early pregnancy doubles risk for gestational diabetes, and gestational diabetes increases risk for postpartum depression.
Gut Pathogens Thrive on Body's Tissue-Repair Mechanism
Researcher have discovered that harm caused by pathogens in the intestinal tract benefit from immune system response to damaged intestinal lining.
Cancer's Taste for Fat
Researchers discovered signalling pathway for fat burning is disrupted in certain cancers.
‘Tracking Bugs’ Reveal Secret of Cancer Cell Metabolism
Unexpected finding shows instead of throwing away valuable nutrients, the cells squeeze out every last drop of energy.
Ginger Nano-Lipid Particles May Improve Cancer Treatment
Edible ginger-derived nano-lipids show promise for effectively targeting and delivering chemotherapeutic drugs used to treat colon cancer.
Genetic Diversity of Enzymes Alters Metabolic Individuality
ToMMo scientists have shown that genetic polymorphisms, structural location of mutation and effect for phenotype correlate with each other.
Absolute Quantification of Mitochondrial Metabolites
Scientists have developed a method to quickly isolate and systematically measure metabolite concentrations within mitochondria.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!